Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous
administration in 4 different quadrants of the abdomen for treatment of opioid use disorder
(OUD). Injection locations are rotated to minimize irritation. Having 1 or more alternate
injection sites is desirable for patients who may be taking SUBLOCADE for extended durations,
based upon clinical response.
The primary objective of this study is to assess the relative bioavailability of
extended-release buprenorphine when administered at alternative injection locations (test
treatments), in comparison to the abdomen (reference treatment).